Cytokinetics Inc


Prices are adjusted according to historical splits.

Cytokinetics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.27 billion
Book Value:
Revenue TTM:
$94.59 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Cytokinetics Inc had its IPO on 2004-04-29 under the ticker symbol CYTK.

The company operates in the Healthcare sector and Biotechnology industry. Cytokinetics Inc has a staff strength of 409 employees.

Stock update

Shares of Cytokinetics Inc opened at $33.37 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $32.96 - $33.64, and closed at $33.36.

This is a -0.8% slip from the previous day's closing price.

A total volume of 692,563 shares were traded at the close of the day’s session.

In the last one week, shares of Cytokinetics Inc have slipped by -9.98%.

Cytokinetics Inc's Key Ratios

Cytokinetics Inc has a market cap of $3.27 billion, indicating a price to book ratio of 31.8985 and a price to sales ratio of 27.5151.

In the last 12-months Cytokinetics Inc’s revenue was $94.59 million with a gross profit of $-146225000 and an EBITDA of $-318388000. The EBITDA ratio measures Cytokinetics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cytokinetics Inc’s operating margin was -342.75% while its return on assets stood at -21.83% with a return of equity of -572.15%.

In Q4, Cytokinetics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 96.5%.

Cytokinetics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-4.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.42. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytokinetics Inc’s profitability.

Cytokinetics Inc stock is trading at a EV to sales ratio of 21.9676 and a EV to EBITDA ratio of -13.9229. Its price to sales ratio in the trailing 12-months stood at 27.5151.

Cytokinetics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.01 billion
Total Liabilities
$84.62 million
Operating Cash Flow
$29.25 million
Capital Expenditure
$3.21 million
Dividend Payout Ratio

Cytokinetics Inc ended 2023 with $1.01 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.01 billion while shareholder equity stood at $-107900000.00.

Cytokinetics Inc ended 2023 with $0 in deferred long-term liabilities, $84.62 million in other current liabilities, 94000.00 in common stock, $-1585994000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $65.58 million and cash and short-term investments were $782.58 million. The company’s total short-term debt was $12,829,000 while long-term debt stood at $63.81 million.

Cytokinetics Inc’s total current assets stands at $795.19 million while long-term investments were $46.71 million and short-term investments were $717.00 million. Its net receivables were $147000.00 compared to accounts payable of $25.61 million and inventory worth $0.

In 2023, Cytokinetics Inc's operating cash flow was $29.25 million while its capital expenditure stood at $3.21 million.

Comparatively, Cytokinetics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Cytokinetics Inc stock is currently trading at $33.36 per share. It touched a 52-week high of $55.8 and a 52-week low of $55.8. Analysts tracking the stock have a 12-month average target price of $61.75.

Its 50-day moving average was $41.11 and 200-day moving average was $44.13 The short ratio stood at 10.98 indicating a short percent outstanding of 0%.

Around 125.7% of the company’s stock are held by insiders while 11576.1% are held by institutions.

Frequently Asked Questions About Cytokinetics Inc

The stock symbol (also called stock or share ticker) of Cytokinetics Inc is CYTK

The IPO of Cytokinetics Inc took place on 2004-04-29

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.


350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080